Prostacyclin in the Treatment of Atherosclerosis Obliterans and Other Vascular Diseases
Prostacyclin is the main arachidonic acid metabolite produced by the arterial walls (2,3,7) and released into circulation (1,4). In man, prostacyclin acts as a powerful vasodilator and anti-platelet agent (13). Resistance vessels are most susceptible for prostacyclin vasodilatory action, while capacitance vessels show little, if any change, even during administration of high doses of prostacyclin (18). The profound anti-platelet effects induced by prostacyclin can be devided into anti-aggregatory and disaggregatory (5,12,13). The former are reflected by a marked inhibition of ADP — or collagen — induced platelet aggregation, the latter by dispersion of both circulating platelet aggregates and platelet thrombi formed on the collagen surface.
KeywordsPulmonary Hypertension Retinal Vein Occlusion Central Retinal Vein Occlusion Pulmonary Artery Hypertension Induce Platelet Aggregation
Unable to display preview. Download preview PDF.
- 6.R.J. Gryglewski, A. Szczeklik, H. Zygulska-Mach, E. Kostaka-Trabka, Prostacyclin and vascular disease. Symposium A. Einstein Coll. of Med., 28–30 October 1980. Raven Press, New York — in press.Google Scholar
- 9.A. Szczeklik, Cardiovascular actions of prostacyclin in man. International conference on prostaglandins, New york, April 1980, in press.Google Scholar
- 10.A. Szczeklik, R.J. Gryglewski, Treatment of vascular disease with prostacyclin. In Clinical pharmacology of prostacyclin, ed. by P. Lewis and J. O’Grady, in press.Google Scholar
- 11.A. Szczeklik, R.J. Gryglewski, Prostaglandins as therapeutical agents in cardiovascular disease. Proceedings of the meeting “Prostaglandins and the cardiovascular system”, Wilrijk (Belgium) 1–3 December 1980, in press (Raven Press).Google Scholar
- 17.A. Szczeklik, J. Szczeklik, R. Nizankowski, P. Gluszko, Prostacyclin for acute coronary insufficiency. Artery — in press.Google Scholar